pasritamig + ARX517

**pasritamig + ARX517** is a combination investigational therapy proposed for advanced or metastatic prostate cancer, in particular metastatic castration-resistant prostate cancer (mCRPC). **ARX517** is an antibody-drug conjugate (ADC) targeting *prostate-specific membrane antigen* (PSMA), composed of a humanized anti-PSMA antibody site-specifically conjugated via a non-cleavable PEG linker to a cytotoxic tubulin inhibitor payload (pAF–AS269). ARX517’s design aims for stable delivery and selective cytotoxicity to PSMA-expressing cancer cells with minimized off-target effects. **Pasritamig** is a distinct candidate drug being tested in oncology, though its precise modality and mechanism remain unpublished in prostate cancer; it is in combination trials with other agents. No evidence was found that the **pasritamig + ARX517** combination is approved or in late-phase clinical trials; rather, ARX517 is in phase 1/2 trials for mCRPC as either a single agent or in combination with enzalutamide, while pasritamig is studied in combination with other agents in early-phase oncology studies[1][2][3][4][5][6][7].